CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ensol Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ensol Biosciences Inc
51, Techno 10-ro, Yuseong-gu
Phone: +82 429394500p:+82 429394500 DAEJEON, 34036  South Korea Ticker: 140610140610
Business Summary
Ensol Biosciences Inc is a Korea-based company primarily engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of 'Peniel2000' (P2K) for degenerative disc disease, 'P2K' indication expansion, 'Engedi1000' (E1K) for knee osteoarthritis, and anticancer combination therapy. The Company is also engaged in the research and development of canine osteoarthritis therapy, 'Moriah1000' (M1K) for alzheimer’s disease (AD), and 'Hadassah1000' (H1K) for oral obesity treatment. In addition, the Company is engaged in the provision of services such as synthesis and purification services, and consulting on of breeding information systems.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8999 Services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
CEO & Founder HaeJinKim

General Information
Number of Employees: 24 (As of 12/31/2024)
Outstanding Shares: 12,268,515 (As of 4/11/2025)
Shareholders: 2,573
Stock Exchange: KON
Fax Number: +82 429354501


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025